e-learning
resources
Munich 2014
Wednesday, 10.09.2014
Antibiotics, antifungals and other therapeutic options
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Comparative evaluation of timing of antibiotic intravenous-to-oral switch in pneumonia
P. Van der Linden, S. Natsch, E. Van de Garde (Hilversum/Blaricum, Utrecht, Nijmegen, Netherlands)
Source:
International Congress 2014 – Antibiotics, antifungals and other therapeutic options
Session:
Antibiotics, antifungals and other therapeutic options
Session type:
Poster Discussion
Number:
4692
Disease area:
Respiratory infections
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
P. Van der Linden, S. Natsch, E. Van de Garde (Hilversum/Blaricum, Utrecht, Nijmegen, Netherlands). Comparative evaluation of timing of antibiotic intravenous-to-oral switch in pneumonia. Eur Respir J 2014; 44: Suppl. 58, 4692
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Management of severe community acquired pneumonia – ERS guidelines
Predictive indexes in prolonged weaning of mechanical ventilation due to tracheostomy in patients with COVID-19 pneumonia
Impact of Dexamethasone on pathogen profile of COVID-19 patients requiring intensive care: a multicentre retrospective study
Related content which might interest you:
Modification of empirical antibiotic therapy in community acquired pneumonia
Source: International Congress 2014 – Different interesting issues in respiratory infections: 2
Year: 2014
Patterns of antibiotic prescribing for pneumonia at the outpatient to inpatient transition
Source: International Congress 2014 – Antibiotics, antifungals and other therapeutic options
Year: 2014
Relationship between the use of inhaled steroids and early outcomes in community-acquired pneumonia
Source: International Congress 2016 – Community-acquired pneumonia: from prevention to treatment
Year: 2016
Healthcare-associated pneumonia: Comparative characteristics with community-acquired pneumonia
Source: International Congress 2015 – CAP: prognostic factors in frail patients
Year: 2015
Shortening duration of antibiotic therapy according to clinical stability in patients with community-acquired pneumonia (CAP)
Source: International Congress 2014 – Respiratory infections: inflammation and treatment
Year: 2014
Dynamic of adherence to guidelines for antibiotic therapy of community-aquired pneumonia (CAP)
Source: Annual Congress 2013 –Antibiotics, resistance and vaccines
Year: 2013
Nursing and healthcare-associated pneumonia requiring hospital admission: Microbiology and clinical outcomes
Source: International Congress 2014 – Epidemiology, scores and outcomes of respiratory infections
Year: 2014
Prior antibiotics and outcomes in patients hospitalized with pneumonia
Source: International Congress 2015 – CAP: prognostic factors in frail patients
Year: 2015
Impact of bacterial coinfection on clinical outcomes in pneumococcal pneumonia
Source: International Congress 2015 – Pneumonia: determinants of clinical outcomes and potential strategies to improve its management
Year: 2015
Empirical treatment of community-acquired pneumonia after outpatient beta-lactam therapy
Source: International Congress 2016 – Community-acquired pneumonia: from prevention to treatment
Year: 2016
Comparison of ampicillin-sulbactam/macrolide dual therapy versus fluoroquinolone monotherapy in hospitalized patients with community-acquired pneumonia
Source: International Congress 2015 – Clinical issues in CAP: microbiological and radiological determinants
Year: 2015
Influence of comorbidities on pneumococcal community-acquired pneumonia
Source: Annual Congress 2013 –Pneumonia and sepsis
Year: 2013
Monitoring of antimicrobial resistance respiratory strains of streptococcus pneumoniae
Source: International Congress 2014 – Different interesting issues in respiratory infections: 1
Year: 2014
Cavitary bacterial lung infections – Predictive factors and outcomes
Source: International Congress 2014 – Different interesting issues in respiratory infections: 1
Year: 2014
Does previous warfarin treatment effect complications and outcome in hospitalised patients with community-acquired pneumonia?
Source: International Congress 2014 – Different interesting issues in respiratory infections: 2
Year: 2014
The neutrophil/lymphocyte ratio in predicting outcome for hospitalized patients with community-acquired pneumonia
Source: International Congress 2014 – Cells, biofilms and biomarkers in respiratory infections
Year: 2014
The prevalence of cardiac diseases in patients with community-acquired pneumonia
Source: International Congress 2014 – Different interesting issues in respiratory infections: 2
Year: 2014
Clinical characteristics of chronic pulmonary aspergillosis and colonization; retrospective analysis of patients with isolation of asperguillus species from respiratory samples
Source: International Congress 2014 – Epidemiology, scores and outcomes of respiratory infections
Year: 2014
Etiological features of nosocomial pneumonia in neurosurgical intensive care unit. Update 2013
Source: International Congress 2014 – Healthcare, prevention and adjunctive treatments in respiratory infections
Year: 2014
Multidrug resistant acinetobacter baumanii pneumonia: Mortality analysis and comparison of intravenous versus aerosolized therapy
Source: International Congress 2014 – Antibiotics, antifungals and other therapeutic options
Year: 2014
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept